Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
On Tuesday, RBC Capital Markets raised its price target on Outset Medical (TASE:BLWV) Inc . (NASDAQ:OM) to $21.00, up from the previous $14.00, while keeping a Sector Perform rating on the stock. The company, currently trading at $19.51, is near its InvestingPro Fair Value estimate. This adjustment follows a fireside chat at the 2025 RBC Global Healthcare Conference, featuring Outset Medical’s CFO, Nabeel Ahmed, and IR, Jim Mazzola.
The new price target reflects a more optimistic valuation of the company’s shares, doubling the previous multiple from 1x to 2x. This change is attributed to Outset Medical’s recent business performance, with the stock showing impressive momentum, gaining over 71% in the past six months. The company maintains strong liquidity with a current ratio of 8.37 and holds more cash than debt on its balance sheet, though InvestingPro data indicates it’s currently unprofitable with negative EBITDA of $84.6 million.
Despite the increased price target, RBC Capital maintains a cautious stance, emphasizing the need for Outset Medical to demonstrate consistent results before considering a more favorable rating. The firm’s current Sector Perform rating indicates a neutral perspective on the stock’s potential performance relative to the broader market. According to InvestingPro, technical indicators suggest the stock is in overbought territory, with analyst targets ranging from $15 to $45. Discover 10+ additional exclusive ProTips and comprehensive analysis in the Pro Research Report.
During the conference, Outset Medical’s executives discussed the company’s progress and strategies. The dialogue provided insights into the company’s operations and future plans, which contributed to RBC Capital’s reassessment of Outset Medical’s valuation.
Outset Medical, known for its innovative medical technology, particularly in the dialysis sector, continues to focus on expanding its market presence and refining its operational strategies. The company’s commitment to improving execution and commercialization efforts has been recognized by RBC Capital, as reflected in the updated price target.
In other recent news, Outset Medical reported a 5.6% increase in revenue year-over-year for the first quarter, reaching $29.8 million. This figure surpassed both Oppenheimer’s and consensus estimates of $28.3 million and $27.8 million, respectively. Despite the revenue beat, the company posted a significant earnings per share (EPS) loss of $3.24, which fell short of analyst expectations of a $0.30 loss. Outset Medical’s recurring revenue grew 20% year-over-year to $22.7 million, with the company maintaining its full-year 2025 revenue guidance between $115 million and $125 million. Oppenheimer analysts maintained a Perform rating on the stock, reflecting cautious optimism amid fundamental challenges in the industry. Additionally, Outset Medical appointed Kevin O’Boyle, a seasoned healthcare executive, to its Board of Directors, replacing Dale E. Jones. This move is expected to strengthen the company’s financial leadership as it navigates its growth strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.